Skip to content
Peptide Atlas
All goals

Peptides Studied for Injury Recovery: What the Research Shows

Recovering from a tendon, ligament, muscle or joint injury involves two linked jobs: rebuilding damaged tissue and calming the inflammation that can stall repair. Several peptides have been studied for one or both jobs, but almost all of the evidence for tissue repair comes from animal and laboratory work, with only small human pilot studies so far. This brief reports what researchers have actually found for each compound.

The biology of this goal

When you injure a tendon, ligament, muscle or joint, the body runs a repair program. First, immune cells rush in and cause inflammation, which clears out damaged material but, if it drags on, can slow healing. Next, the body needs to build new blood vessels to bring in oxygen and nutrients, and it needs cells called fibroblasts to lay down collagen — the tough protein that forms the scaffolding of tendons, ligaments and skin. Repair cells also have to physically crawl to the injury site to do their work. Tendons and ligaments heal slowly because they have a poor blood supply, so anything that improves blood-vessel growth or collagen building is of interest for recovery. The peptides in this brief are being studied because they touch one or more of these steps: settling inflammation, growing blood vessels, or helping cells migrate and rebuild tissue.

What the research supports

8 of 14 relevant, from 15 considered

TB-500

Tier 2 · Preclinical

Human trials report Tβ4-related effects on cardiac ejection fraction, but for musculoskeletal injury the direct human evidence is limited to a small retrospective knee-pain series and mostly rodent models.

TB-500 is a lab-made peptide related to thymosin beta-4, a small protein found naturally in nearly every human cell. Its central action is grabbing the cell building-block protein actin, which lets repair cells move to injury sites and reorganize. In animal studies it has been linked to new blood-vessel growth, calmer inflammation and tissue repair, including in muscle and tendon.

  • In a retrospective series, 3 of 4 patients (75%) who received a combination of BPC-157 and TB4 intra-articular knee injections showed significant improvement in knee pain, while 1 had no relief.1

  • Across all 16 patients treated with BPC-157 or the BPC-157/TB4 combination, 14 (87.5%) reported relief of knee pain.1

  • In rodent models, Tβ4 has shown accelerated wound healing, increased angiogenesis, and support for skeletal muscle and tendon recovery.2

  • A double-blind placebo-controlled European study (n=73) found 0.03% topical TB-500 produced complete healing in about 25% of venous stasis ulcer patients within 3 months, though overall healing rates were not conclusively superior to control.2

  • March 2024 research reported that TB-500 (Ac-LKKTETQ) did not enhance wound healing activity, whereas its metabolite Ac-LKKTE did.2

  • TB4 can preserve ejection fraction in animal studies of cardiac injury.3

What this doesn't establish

No controlled human trial establishes that the injected TB-500 fragment rebuilds injured tendon, ligament or muscle tissue in people; the knee-pain data combined it with BPC-157 in only four patients and could not isolate its effect.

BPC-157

Tier 2 · Preclinical

Human trials of BPC-157 exist but are limited to three small pilot studies; the musculoskeletal repair evidence remains overwhelmingly preclinical.

BPC-157 is a synthetic 15-amino-acid peptide originally identified in human gastric juice. Animal studies describe it promoting new blood-vessel growth and helping cells migrate to repair soft tissue, which is why it has drawn interest for tendon, ligament and muscle injury. It appears especially active in poorly-supplied tissues like tendons and ligaments.

  • BPC-157 engages ERK1/2 signaling and facilitates endothelial and muscle repair, promoting angiogenesis, fibroblast activity and neuromuscular stabilization.4

  • Experimental evidence shows BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity and modulation of nitric oxide pathways, and it has pain-modulating effects through peripheral and dopaminergic mechanisms.5

  • Across studies, BPC-157 has demonstrated consistently positive and prompt healing effects for various injury types, and shows potential for hypovascular, hypocellular tissues such as tendon and ligaments.6

  • Skeletal muscle injury models suggest benefit not only after direct trauma but also for systemic insults including hyperkalemia and hypermagnesemia.6

  • Human research remains limited to only three small pilot studies, covering intraarticular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetics.4,5

What this doesn't establish

Consistent healing effects in rodents have not been confirmed in adequately powered human trials, so its efficacy for rebuilding injured human tendon, ligament or muscle is not established.

Semax

Tier 2 · Preclinical

Human trials report Semax improves functional recovery after ischemic stroke, but its relevance to musculoskeletal injury rests on animal neural-injury models, not human tendon or joint data.

Semax is a lab-made seven-amino-acid peptide based on a fragment of the hormone ACTH, with an added tail that removes ACTH's hormonal action. Most of its research is in the brain and nerve tissue rather than tendons or joints. In injury models it raises brain growth factors and appears to dial down inflammation and oxidative stress while switching on genes tied to repair and new blood vessels.

  • In stroke patients, early rehabilitation with semax increased plasma BDNF levels, sped functional recovery and improved motor performance.8

  • Semax improved functional recovery in a spinal cord injury mouse model by targeting μ-opioid receptors, which regulated USP18 and subsequent deubiquitination of FTO.7

  • Semax acts on the μ-opioid receptor with downstream effects on lysosomal membrane permeabilization, oxidative stress and pyroptosis after spinal cord injury.9

What this doesn't establish

There is no evidence that Semax repairs tendon, ligament, muscle or joint tissue; its recovery data concern the brain and spinal cord.

GHK-Cu

Tier 2 · Preclinical

Animal and laboratory studies suggest GHK-Cu improves tissue and graft healing, but there is a current lack of clinical trials for injury recovery.

GHK-Cu is a naturally occurring three-amino-acid peptide bound to copper, present in human plasma and released when tissue is injured. It signals skin and connective-tissue cells to make more collagen and other building blocks, promotes new blood-vessel growth, and calms inflammation. Researchers have tested it for wound healing and, in animals, for ligament graft healing.

  • GHK-Cu is a naturally occurring tripeptide present in human plasma, released from tissues upon injury, and stimulates wound healing across skin, lung connective tissue, bone, liver and stomach lining.10

  • GHK-Cu promotes angiogenesis, integrin-mediated extracellular matrix remodeling and fibroblast activation through pathways central to tissue regeneration and inflammation resolution.11

  • In a rat ACL reconstruction model, GHK-Cu groups had smaller side-to-side knee laxity than saline at 6 weeks (p=0.009), but no significant difference remained at 12 weeks after treatment was discontinued.12

  • Preclinical studies of wound-healing peptides like GHK-Cu are promising but clinical trials are currently lacking.11

What this doesn't establish

Even in the strongest animal data, the benefit was transient: improvement in ligament graft healing did not persist once treatment stopped, and no human injury trials confirm the effect.

GLOW

Tier 3 · Reported use

For the GHK-Cu component, human-tier gene and wound-healing data exist, but for the GLOW blend as a whole this is theoretical; no direct study supports the combination for injury recovery.

GLOW is not a single drug but a marketed blend of three separately studied peptides — GHK-Cu, BPC-157 and TB-500 — combined for skin quality and recovery. The idea is that each contributes to repair from a different angle. The claimed advantage of the combination itself rests on theoretical synergy and user reports, not on studies of the blend.

  • GHK-Cu, a naturally occurring tripeptide present in human plasma and released upon injury, stimulates wound healing across skin, lung connective tissue, bone, liver and stomach lining.13,14

  • BPC-157, one component, is known for promoting wound healing and injury recovery.15

  • Some people who use BPC-157 have reported injection site pain and swelling, including redness or skin changes.15

What this doesn't establish

No study has tested GLOW as a formulation for injury recovery, so any added benefit from combining the three peptides is unproven, and injectable peptides carry reported injection-site reactions.

KPV

Tier 3 · Reported use

Community reports and practitioner commentary describe KPV as anti-inflammatory and healing-supportive, with the underlying data coming from animal and cell studies rather than human injury trials.

KPV is a three-amino-acid fragment (Lys-Pro-Val) from the tail of the hormone alpha-MSH, and most sources describe it as calming inflammation. Because persistent inflammation can stall healing, it is of interest for the inflammatory side of injury recovery. It is being explored for wound healing and skin inflammation, mainly in gut and cell models so far.

  • Animal model studies have shown KPV may reduce intestinal permeability and support mucosal healing.16

  • Researchers are exploring KPV in wound healing and skin inflammation contexts, and cell research suggests it could support skin healing.16,17

  • The FDA has been evaluating KPV for wound healing and inflammatory conditions such as colitis.18

What this doesn't establish

Human clinical trial data remain very limited and formal safety trials have not been completed, so its effect on healing musculoskeletal injury in people is unestablished.

Elafin

Tier 1 · Human trials

Human trials report that elafin engages its target enzyme but, in its most rigorous test, did not reduce myocardial injury or inflammation markers over 48 hours.

Elafin is a human protein made naturally in skin, lung and other tissues that protects tissue from immune-driven destruction by blocking enzymes involved in inflammation. It rises at sites of injury. Because these tissue-destroying enzymes increase in inflammatory damage, researchers have tested giving extra elafin to limit that damage.

  • Elafin is a potent endogenous neutrophil elastase inhibitor that protects against inflammation and injury in preclinical ischaemia-reperfusion models.19,21

  • In a randomised placebo-controlled trial of 87 CABG patients, elafin raised plasma levels over 3000-fold and inhibited over 50% of elastase activity but did not reduce myocardial injury over 48 hours (troponin I AUC ratio 0.74, 95% CI 0.47–1.15, p=0.18).19,21

  • Trappin-2 is present in many tissues and is upregulated at sites of injury; osteoarthritic cartilage contained significantly higher levels than normal cartilage (22.98 vs 14.97 ng/mg, p<0.01).20

What this doesn't establish

The one large human trial addressed heart-surgery ischemia-reperfusion, not tendon, ligament, muscle or joint injury, and its primary healing/injury endpoint was negative.

Imunofan

Tier 2 · Preclinical

Human data report that imunofan, combined with other therapy, helped convert chronic wound inflammation into an active repair phase, though this evidence concerns trophic ulcers rather than musculoskeletal injury.

Imunofan is a small synthetic peptide modeled on a fragment of thymopoietin, a natural thymic hormone that guides immune T-cells. It is described as an immunomodulator that nudges an out-of-balance immune system back toward normal rather than simply revving it up, and it is credited with antioxidant actions and with stimulating tissue repair. It has been studied as part of combination treatment for chronic wounds.

  • In elderly patients with venous trophic ulcers, complex treatment including Imunofan immune correction helped convert chronic inflammation into acute inflammation with initiation of reparation and tissue regeneration, with regenerative cytograms by day 22.23

  • The synthetic hexapeptide RDKVYR was assessed for potential efficacy in stimulating tissue repair and wound healing.24

  • In rats, intramuscular imunofan altered pain sensitivity and behaviour depending on individual stress resistance, indicating immune stimulation influences pain responses.22,22

What this doesn't establish

The human evidence is from venous trophic ulcers using combination treatment, so imunofan's independent effect on tendon, ligament, muscle or joint repair is not established.

How they work together

Check this stack

Several of these compounds are described as complementary because they attack different steps of the same repair process. BPC-157 and TB-500 are frequently discussed as a complementary healing pair because they drive repair through entirely different targets — BPC-157 through VEGF/nitric oxide signaling, TB-500 through actin regulation. BPC-157 and GHK-Cu likewise overlap on wound healing, collagen synthesis and angiogenesis but enter through distinct routes, and are often combined for skin and connective-tissue remodeling; GHK-Cu and TB-500 pair the same way. On the inflammation side, KPV and elafin both restrain NF-κB-driven mucosal inflammation but by different means — KPV suppresses inflammatory cytokines while elafin blocks tissue-destroying proteases — and KPV pairs plausibly with TB-500 (one quiets inflammation, the other rebuilds tissue) and with BPC-157 for gut healing. Imunofan is described as complementing elafin, KPV and TB-500 by adding immune-balancing and antioxidant actions through a separate mechanism. GHK-Cu and KPV reach an anti-inflammatory endpoint by distinct NF-κB routes with nothing described suggesting conflict. These pairings reflect mechanistic reasoning and curated relationship data, not head-to-head trials of the combinations.

  • BPC-157 + GHK-Cu

    May be complementary

    Both peptides promote wound healing, collagen synthesis and angiogenesis through overlapping PI3K/Akt, mTOR, TGF-β and AMPK signaling, but via distinct entry points: BPC-157 through VEGFR2/eNOS and growth-factor induction, GHK-Cu through copper delivery, lysyl-oxidase-driven collagen/elastin crosslinking and Nrf2 antioxidant activation. They are frequently combined for skin/connective-tissue remodeling.

  • BPC-157 + TB-500

    May be complementary

    BPC-157 and TB-500 drive tissue repair through entirely different molecular targets (VEGF/NO signalling vs. actin regulation), so they are frequently discussed as a complementary healing pair rather than a redundant one.

  • Elafin + KPV

    May be complementary

    Both dampen inflammation at mucosal surfaces largely by restraining NF-κB signaling, but by different means: KPV (an α-MSH fragment) suppresses inflammatory cytokines and stabilizes IκBα, while elafin blocks tissue-destroying proteases. In a gut/mucosal setting they address inflammation and barrier protection from complementary angles.

  • Elafin + TB-500

    May be complementary

    TB-500 promotes cell migration, angiogenesis and matrix remodeling for wound healing, while elafin protects healing tissue by inhibiting neutrophil proteases and suppressing NF-κB inflammation. Distinct mechanisms both favoring tissue repair.

  • GHK-Cu + TB-500

    May be complementary

    GHK-Cu stimulates collagen/GAG synthesis and ECM remodeling while TB-500 (Thymosin β4 fragment) sequesters G-actin to promote cell migration, angiogenesis and inflammation resolution. Different mechanisms both converge on angiogenesis, integrin/ECM remodeling and NF-κB suppression — a classic complementary regeneration pairing.

  • BPC-157 + KPV

    No known conflict in the research

    Both are studied for gut healing and inflammation. BPC-157 provides mucosal cytoprotection and microvascular repair, while KPV suppresses NF-kB and pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and protects the intestinal epithelial barrier. Different mechanisms converging on gut mucosal recovery, making them a plausible complementary GI pairing.

  • Elafin + Imunofan

    No known conflict in the research

    Imunofan is a thymopoietin-based immunomodulator that boosts phagocytic/antimicrobial defenses and supports tissue repair, complementing elafin's antiprotease and antimicrobial actions. Different mechanisms supporting immune balance and mucosal repair.

  • GHK-Cu + KPV

    No known conflict in the research

    Both GHK-Cu and KPV reduce inflammation and lower pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), each acting on NF-κB signaling. GHK-Cu suppresses NF-κB alongside copper-dependent antioxidant enzyme support, while KPV, an α-MSH fragment, stabilizes IκBα and inhibits the IKK complex. They reach an anti-inflammatory endpoint by distinct routes. Nothing described suggests a conflict between them.

  • Imunofan + KPV

    No known conflict in the research

    KPV is a potent NF-κB-suppressing anti-inflammatory (lowering TNF-α, IL-1β, IL-6) with mucosal/antimicrobial activity, working through a different mechanism than imunofan's thymic immunocorrection. Both push toward calmer inflammation and better mucosal defense, making them a plausible complementary anti-inflammatory pairing.

  • Imunofan + TB-500

    No known conflict in the research

    TB-500 drives cytoskeletal-based cell migration, angiogenesis and NF-κB-suppressing anti-inflammatory repair. This converges with imunofan's reported fibroblast/keratinocyte stimulation and anti-inflammatory cytokine modulation through an entirely different mechanism, supporting a complementary tissue-recovery goal.

  • KPV + TB-500

    No known conflict in the research

    KPV dampens the inflammatory cytokine signal (TNF-α, IL-6, NF-κB), while TB-500 drives the structural side of repair through actin/cytoskeletal dynamics, angiogenesis and cell migration. One quiets inflammation, the other rebuilds tissue — a complementary pairing for wound and mucosal healing.

9 other pairings have no documented interaction in our data — that is not a safety clearance.
  • BPC-157 + Elafin
  • BPC-157 + Imunofan
  • BPC-157 + Semax
  • Elafin + GHK-Cu
  • Elafin + Semax
  • GHK-Cu + Imunofan
  • GHK-Cu + Semax
  • Imunofan + Semax
  • Semax + TB-500

Compounds we looked at and left out

These share some biology with this goal, so you may have seen them recommended for it. Here is what our own research says about each.

  • HCGmatched on new blood-vessel growth

    HCG is linked to new blood-vessel growth, but in this compound that activity is about promoting angiogenesis in the uterine endometrium during pregnancy.

What we can't tell you yet

Almost all tissue-repair evidence here is preclinical or from small pilot studies; no adequately powered human trial confirms that any of these compounds rebuilds injured tendon, ligament, muscle or joint tissue. The strongest human trials point elsewhere — stroke recovery for semax, cardiac surgery for elafin, trophic ulcers for imunofan — so their relevance to musculoskeletal injury is inferred rather than demonstrated. There is no data on the GLOW blend tested as a formulation.

Pairings we could not confirm

  • KPV + Semax: proposed as compatible, but the two compounds' own mechanism data did not support the pairing.

Sources

Ordered as cited above.

  1. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  2. TB-500 - Status, Risks, and Bans in Sport and Military | Blog(opens in a new tab)
    Tier 3Web · bscg.org
  3. Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  4. Regeneration or Risk? A Narrative Review of BPC-157 for ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  5. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management(opens in a new tab)
    Tier 1Web · mdpi.com
  6. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  7. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  8. [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. - Abstract - Europe PMC(opens in a new tab)
    Tier 1Web · europepmc.org
  9. Semax and N Acetyl Semax-Amide: discovery, actions, safety, animal data, and development(opens in a new tab)
    Tier 2Web · hvm.bioflux.com.ro
  10. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data(opens in a new tab)
    Tier 2Web · mdpi.com
  11. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  12. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  13. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  14. Regenerative and Protective Actions of the GHK-Cu Peptide in ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov
  15. 4 Dangerous Side Effects of Peptide Injections(opens in a new tab)
    Tier 3Web · verywellhealth.com
  16. KPV Peptide: Uses, Safety, and Why the FDA Is About to Review It(opens in a new tab)
    Tier 3Web · doctronic.ai
  17. FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns(opens in a new tab)
    Tier 3Web · health.com
  18. What to Know About the 6 Peptides Backed by an FDA Advisory Panel(opens in a new tab)
    Tier 3Web · verywellhealth.com
  19. Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial - University of Edinburgh Research Explorer(opens in a new tab)
    Tier 1Web · research.ed.ac.uk
  20. The serine protease inhibitor trappin-2 is present in cartilage and synovial fluid in osteoarthritis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  21. Perioperative elafin for ischaemia-reperfusion injury during coronary artery bypass graft surgery: a randomised-controlled trial(opens in a new tab)
    Tier 1Web · doi.org
  22. [Nociceptive reactions during stimulation of immunity in rats with various individual resistance to stress].(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov
  23. [Effectiveness of local treatment of venous trophic ulcers in gerontological patients].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov
  24. Imunofan—RDKVYR Peptide—Stimulates Skin Cell Proliferation ...(opens in a new tab)
    Tier 2Web · pmc.ncbi.nlm.nih.gov

This brief reports what published research says about these compounds. It is information, not medical advice, and not a recommendation to use anything described here. Evidence quality varies by compound and is labelled throughout. Talk to a qualified clinician before acting on any of it.

See something wrong or out of date on this page? Report it.